UAB To Test Potential COVID-19 Vaccine
By BirminghamWatch
The University of Alabama at Birmingham and the biopharmaceutical company Altimmune Inc. will test a potential vaccine for COVID-19, the university announced today.
Testing of the vaccine, AdCOVID, which was developed by the company based in Gaithersburg, Maryland, will begin in mice during the second quarter of this year. That phase of testing, designed to show the immune response to the drug in mice, is expected to take one to two months, UAB said in announcing the collaboration.
The vaccine is given in a single dose of intranasal spray, UAB said. If results of the tests in mice warrant, Altimmune could launch a Phase 1 human safety trial during the third quarter of this year.
The announcement by UAB said Altimmune “has significant experience in the development of intranasal vaccine candidates for respiratory pathogens, including a seasonal and pandemic influenza vaccine and a vaccine for inhalation anthrax.”
“We are eager to collaborate with Altimmune on this important project,” said Frances E. Lund, the Charles H. McCauley Professor and Chair for the UAB Department of Microbiology. “The expertise and infrastructure at UAB will be invaluable to the rapid progression of this vaccine into clinical studies.
Lund said six labs at UAB will work on the project.
Vipin K. Garg, president and CEO of Altimmune, cited UAB’s role in research in virology and immunology. He said the company was founded through a technology license from UAB in 1997.
“It is critical that the biotechnology industry and academic institutions work together to prevent the further spread of COVID-19, and UAB is an ideal partner to support us in this effort,”Garg said.
UAB also has extensive experience in conducting clinical studies of vaccines and has participated in studies sponsored by the Vaccine Evaluation and Trial Unit, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
The vaccine being tested “will activate mucosal and cellular immune responses, as well as a strong antibody response in the blood,” the announcement said.
“If the AdCOVID vaccine candidate is as stable as Altimmune’s influenza and anthrax vaccines candidates, that may allow inexpensive and efficient distribution of the millions of doses needed for widespread vaccination of populations,” the statement said.
How George Wallace and Bull Connor set the stage for Alabama’s sky-high electric rates
After his notorious stand in the schoolhouse door, Wallace needed a new target. He found it in Alabama Power.
FIFA president defends World Cup ticket prices, saying demand is hitting records
The FIFA President addressed outrage over ticket prices for the World Cup by pointing to record demand and reiterating that most of the proceeds will help support soccer around the world.
From chess to a medical mystery: Great global reads from 2025 you may have missed
We published hundreds of stories on global health and development each year. Some are ... alas ... a bit underappreciated by readers. We've asked our staff for their favorite overlooked posts of 2025.
The U.S. offers Ukraine a 15-year security guarantee for now, Zelenskyy says
Ukrainian President Volodymyr Zelenskyy said Monday the United States is offering his country security guarantees for a period of 15 years as part of a proposed peace plan.
Genre fiction and female authors top U.S. libraries’ most-borrowed lists in 2025
All of the top 10 books borrowed through the public library app Libby were written by women. And Kristin Hannah's The Women was the top checkout in many library systems around the country.
The Best Tiny Desk Concerts of 2025
Which Tiny Desk made an audio engineer question everything? Which one made a producer want to cry? Touch grass? Look back on the year in Tiny Desk, with the people who make them.
